NantKwest Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
600.00
641.00
236.00
44.00
45.00
47
SG&A Expense
2,865.00
6,180.00
237,640.00
120,937.00
93,599.00
88,881
EBIT
-
-
238,876.00
124,500.00
99,120.00
98,389
Unusual Expense
684.00
158.00
1,366.00
-
-
-
Non Operating Income/Expense
-
-
2,791.00
199.00
194.00
239
Interest Expense
463.00
471.00
-
66.00
618.00
433
Pretax Income
2,046.00
6,184.00
237,177.00
121,381.00
96,916.00
96,729
Income Tax
1.00
1.00
301.00
572.00
493.00
503
Consolidated Net Income
2,047.00
6,185.00
236,876.00
120,809.00
96,423.00
96,226
Net Income
2,047.00
6,185.00
236,876.00
120,809.00
96,423.00
96,226
Net Income After Extraordinaries
2,047.00
6,185.00
236,876.00
120,809.00
96,423.00
96,226
Net Income Available to Common
2,047.00
6,185.00
236,876.00
120,809.00
96,423.00
96,226
EPS (Basic)
2.57
0.75
3.31
1.47
1.20
1.22
Basic Shares Outstanding
797.10
8,246.00
71,519.60
81,979.00
80,583.90
79,132.20
EPS (Diluted)
2.57
0.75
3.31
1.47
1.20
1.22
Diluted Shares Outstanding
797.10
8,246.00
71,519.60
81,979.00
80,583.90
79,132.20
EBITDA
2,265.00
5,539.00
237,404.00
120,893.00
93,554.00
88,834
Non-Operating Interest Income
2.00
20.00
274.00
2,986.00
2,628.00
1,854

About NantKwest

View Profile
Address
3530 John Hopkins Court
San Diego California 92121
United States
Employees -
Website http://www.nantkwest.com
Updated 07/08/2019
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.